Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending February 17, 2017. The report details the vesting outcomes of Deferred Bonus Awards and Matching Awards granted in 2014 under the 2009 Deferred Annual Bonus Plan (DABP). The three-year performance period for these awards concluded on December 31, 2016, with vesting notifications issued on February 16, 2017.
Key Financial Metrics and Performance Outcomes
The filing does not report consolidated revenue, profit, cash flow, or debt metrics for the company. Instead, it focuses on specific performance measures tied to executive compensation:
- Adjusted Free Cash Flow: The Company did not meet the threshold level of performance for the three-year period. Result: 0% vesting (Lapsed in full).
- Total Shareholder Return (TSR): GSK ranked 9th out of 10 global pharmaceutical companies (below median). Result: 0% vesting (Lapsed in full).
- R&D New Products Sales: Achieved sales of £6.717 billion, exceeding the maximum vesting level of £4.428 billion (threshold was £3.623 billion). Adjustments were made for the Novartis transaction. Result: 100% vesting for this portion (33.33% of total award).
- Overall Vesting Outcome: 66.67% of the 2014 awards lapsed; 33.33% vested.
- Share Prices at Vesting: Ordinary Share: £16.17; American Depositary Share (ADS): $40.92.
Material Changes and Transactions
The primary material event is the release of shares to Persons Discharging Managerial Responsibilities (PDMRs) following the performance period. The filing lists specific transactions for nine executives, including CEO Sir Andrew Witty and CEO Designate Ms Emma Walmsley. All transactions occurred on February 16, 2017, on the London Stock Exchange (XLON) or via ADS mechanisms. The shares were released at a price of £0.00 or $0.00 as they were compensation awards, not market purchases.
| Executive | Position | Instrument | Total Shares/ADSs Released |
|---|---|---|---|
| Sir Andrew Witty | CEO | Ordinary Shares | 90,488 |
| Ms Emma Walmsley | CEO Designate | Ordinary Shares | 19,814 |
| Mr S Dingemans | CFO | Ordinary Shares | 29,931 |
| Dr P J T Vallance | President, R&D | Ordinary Shares | 35,817 |
| Dr M M Slaoui | Chairman, Global Vaccines | ADSs | 28,860 |
| Mr D E Troy | SVP & General Counsel | ADSs | 11,682 |
Additional awards were released to Mr R G Connor, Mr S A Hussain, Mr D S Redfern, Ms C Thomas, and Mr P C Thomson.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future strategy, or discussion of general corporate risks. The document is strictly a notification of past performance outcomes regarding executive compensation. The only noted contingency was the adjustment of R&D sales figures to account for the implications of the three-part transaction with Novartis.
Investor Verification Checklist
- Verify the specific performance thresholds for the 2014 DABP in the original plan documents to confirm the £4.428bn maximum vesting level for R&D sales.
- Confirm the impact of the Novartis transaction on the reported £6.717bn R&D sales figure.
- Review the full list of PDMRs to ensure all eligible executives received the 33.33% vesting proportion.
- Check subsequent filings for the actual market sale of these vested shares by executives, as this filing only reports the release of shares.